19 January 2016 - EU Marketing Authorization offers the potential for broader access to Oncaspar as Baxalta continues to build its innovative and diverse portfolio of differentiated oncology treatments.

For more details, go to: http://newsroom.baxalta.com/press-releases/press-release-details/2016/Baxalta-Granted-EU-Marketing-Authorization-for-ONCASPAR-pegaspargase-as-a-Component-of-Combination-Therapy-in-Acute-Lymphoblastic-Leukaemia-ALL/default.aspx